Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

• Published in: Cancers Vol. 14; no. 14; p. 3524
• Main Authors: Marin, Jose, Monte, Maria, Macias, Rocio, Romero, Marta, Herraez, Elisa, Asensio, Maitane, Ortiz-Rivero, Sara, Cives-Losada, Candela, Di Giacomo, Silvia, Gonzalez-Gallego, Javier, Mauriz, Jose, Efferth, Thomas, Briz, Oscar
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-07-2022; MDPI
• Subjects: Antimitotic agents; Antineoplastic agents; Cancer; Cancer therapies; Chemoresistance; Chemotherapy; Development and progression; Drug resistance in microorganisms; Drug therapy; Gastrointestinal diseases; Glycoproteins; Health aspects; Immunomodulation; Kinases; Liver cancer; MDR1 protein; Medical prognosis; Mortality; Multidrug resistance; P-Glycoprotein; Pancreas; Pancreatic cancer; Phenotypes; Protein binding; Proteins; Review; Stem cells; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14143524

Hepatobiliary, pancreatic, and gastrointestinal cancers account for 36% of the ten million deaths caused by cancer worldwide every year. The two main reasons for this high mortality are their late diagnosis and their high refractoriness to pharmacological treatments, regardless of whether these are based on classical chemotherapeutic agents, targeted drugs, or newer immunomodulators. Mechanisms of chemoresistance (MOC) defining the multidrug resistance (MDR) phenotype of each tumor depend on the synergic function of proteins encoded by more than one hundred genes classified into seven groups (MOC1-7). Among them, the efflux of active agents from cancer cells across the plasma membrane caused by members of the superfamily of ATP-binding cassette (ABC) proteins (MOC-1b) plays a crucial role in determining tumor MDR. Although seven families of human ABC proteins are known, only a few pumps (mainly MDR1, MRP1-6, and BCRP) have been associated with reducing drug content and hence inducing chemoresistance in hepatobiliary, pancreatic, and gastrointestinal cancer cells. The present descriptive review, which compiles the updated information on the expression of these ABC proteins, will be helpful because there is still some confusion on the actual relevance of these pumps in response to pharmacological regimens currently used in treating these cancers. Moreover, we aim to define the MOC pattern on a tumor-by-tumor basis, even in a dynamic way, because it can vary during tumor progression and in response to chemotherapy. This information is indispensable for developing novel strategies for sensitization.